Benzinga | Feb 2, 2021 11:49AM EST

Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $31

Canaccord Genuity analyst Max Masucci maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $31.